OTCM
ACIXF
Market cap24mUSD
Oct 14, Last price
0.02USD
Name
Acarix AB
Chart & performance
P/E
—
P/S
28.34
EPS
—
Vol. 1Y
—
Shs. 5Y
60.28%
Rev. 5Y
27.67%
Div Yld LY
—
Div Yld TTM
—
Revenues
7m
+18.69%
Net income
-48m
L-27.34%
CFO
-48m
L-23.60%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADScor System, an exceptionally sensitive, non-invasive analytical device designed for the detection of coronary artery disease. Founded in 2009, Acarix AB (publ) maintains its headquarters in Malmö, Sweden.
Key people
Jan Poulsen
Chairman of the Board · since 2025
Aamir Mahmood
President, Chief Executive Officer · since 2024
Christian Lindholm
Chief Financial Officer · since 2021
Daniel Burke
Head of Reimbursement & Market Access · since 2025
George Chrysant
Chief Medical Advisor · since 2024
Carma Connely
Head of Operations & Customer Excellence · since 2024
Jennifer Matson
Head of Medical Affairs · since 2022
Dwyndl Nelms
Head of QA, RA & Production · since 2024
Jeffrey Rudd
Head of U.S. Finance · since 2025
Jeff Thomas
Head of U.S. Sales · since 2024
Tony Das
Independent Director · since 2024
Marlou Janssen-Counotte
Independent Director · since 2020
Independent Director · since 2024
Headquarters & legal address
HYLLIE BOULEVARD 34 5 TR
MALMÖ, M 215 32
SE
MALMÖ, M 215 32
SE
Previous name
Acarix AB (publ)
Previous name
Goldcup 10596 AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||